Email updates

Keep up to date with the latest news and content from Vascular Cell and BioMed Central.

Open Access Highly Accessed Review

Vaccines targeting the neovasculature of tumors

Agata Matejuk12, Qixin Leng1, Szu-Ting Chou1 and Archibald J Mixson1*

Author Affiliations

1 Department of Pathology, University of Maryland Baltimore, MSTF Building, 10 South Pine Street, Baltimore, MD 21201, USA

2 Department of Plastic Surgery, Microsurgery Laboratory, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland Ohio 44195, USA

For all author emails, please log on.

Vascular Cell 2011, 3:7  doi:10.1186/2045-824X-3-7

Published: 8 March 2011

Abstract

Angiogenesis has a critical role in physiologic and disease processes. For the growth of tumors, angiogenesis must occur to carry sufficient nutrients to the tumor. In addition to growth, development of new blood vessels is necessary for invasion and metastases of the tumor. A number of strategies have been developed to inhibit tumor angiogenesis and further understanding of the interplay between tumors and angiogenesis should allow new approaches and advances in angiogenic therapy. One such promising angiogenic approach is to target and inhibit angiogenesis with vaccines. This review will discuss recent advances and future prospects in vaccines targeting aberrant angiogenesis of tumors. The strategies utilized by investigators have included whole endothelial cell vaccines as well as vaccines with defined targets on endothelial cells and pericytes of the developing tumor endothelium. To date, several promising anti-angiogenic vaccine strategies have demonstrated marked inhibition of tumor growth in pre-clinical trials with some showing no observed interference with physiologic angiogenic processes such as wound healing and fertility.